Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

Sign in Join

June 23 – 29, 2025

Psychedelic Bulletin #202

Psychedelic Alpha ↗

  • RFK Jr. Envisages Psychedelics Access ‘Within 12 Months’
  • Psychedelics in Washington: FDA, VA, and New Political Signals
  • Lykos Therapeutics’ New CEO and CMO, Amy Emerson Joins Board
  • New Zealand Approves First Psilocybin Prescriber
  • DEA Judge Recommends Schedule I Placement for DOI and DOC
  • First Legal Psilocybin Sessions in Colorado
  • GH Research Submits IND Hold Response as 5-MeO-DMT Race Heats Up
  • Dutch Cabinet Responds to MDMA State Commission
  • and more…

June 16 – 22, 2025

June 9 – 15, 2025

Psychedelic Bulletin #201

Psychedelic Alpha ↗

  • The Psychedelics Circuit: Dispatches from Prague and London, Looking Ahead to Denver
    • EU Member States as Laboratories of Democracy? Conference Discusses Czechia’s Psychedelic Future at Prague Castle
    • At ‘the Davos of Mental Health’, Investors Eye Psychedelics’ Next Chapter
    • Join Us in Denver: Psychedelic Alpha at Psychedelic Science 2025
  • High-Dose LSD Shows Potential in Depression Trial, But Findings Are Fragile
  • Lone Star State Becomes Leader in Ibogaine Research
  • One-Year Outcomes from Psilocybin Study in Veterans with TRD
  • A Series of Unfortunate Events: Recent Incidents Underscore Psychedelic Safety
  • and more…

June 2 – 8, 2025

Psychedelic Bulletin #200

Psychedelic Alpha ↗

  • The Class of Bulletin 100: Where Are They Now?
  • Can Czechia Deliver on Psilocybin Access and Provide a Model for the Continent?
  • A Closer Look at atai’s Potential Acquisition of Beckley Psytech
  • Q1’25 Psychedelic Lobbying Update
  • Holy Trips and Hot Takes: Religious Leaders Study Finally Published
  • and more…

May 26 – June 1, 2025

Pα+ Psychedelic Bulletin #199

Psychedelic Alpha ↗

  • New CEO Tapped as Gracias and Hohn Close In on Lykos Therapeutics Takeover
  • Data Reveals Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access
  • Ibogaine Bill Clears Texas Legislature Amid THC Crackdown
  • and more…

Amanda Feilding

Drug Science ↗

“Her legacy is one of courage, curiosity, and an unshakable belief in the power of love over fear.”

Pα+

An insider’s guide to the business,
policy and science of psychedelics.

Basic

Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.

Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.

Monthly $20 Annually $200

Teams

Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.

Benefits

Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.

Learn More
  Free
Weekly Psychedelic News Feed
Occasional Articles & Free Resources
Psychedelic Bulletins (In-Depth Briefings, Multiple per Month)
Quick-Take Analysis of Major Developments
In-Depth Articles & Deep Dives
Exclusive Interviews with Insiders & KOLs
Quarterly Video Briefings
Exclusive Tools & Data Resources
Library of Primers & Explainers

Subscribe Now

Monthly $20 Annually $200

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.